The news of the cimi

Publication – O Silvie

O. Silvie’s team has identified a Plasmodium protein that is essential for the infection of hepatocytes during malaria. This protein, called B9, could constitute a new vaccine target.

Publication – D Scalbert Sterlin

A novel CIMI collaboration underlines the key role played by the immune/microbiota interface in the pre-education of the human antibody repertoire.

Team’s FRM 2022 – G Gorochov

Guy Gorochov’s team has been awarded the Equipe FRM 2022 label for the project «Study and manipulation of host-microbiota mutualism regulated by immunoglobulin A»

“Lower disease activity but higher risk of severe COVID- 19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α”

New Publication – Allon Weiner’s team

Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage.

The effectiveness of a vaccine against #HIV

Dr behazine combadière, a lead investigator at the centre for immunology and infectious diseases @inserm is working on predicting the effectiveness of a vaccine against #hiv which is concurrently advancing the #covidvaccine development research.

Vaccine responses against SARS-CoV-2 variants examined in people with lupus

The majority of people with systemic lupus erythematosus (SLE) who respond to messenger (m)RNA COVID-19 vaccines also generate an antibody response against emerging SARS-CoV-2 variants, albeit with reduced neutralizing activity against variants bearing the E484K mutation, researchers report.

Is it dangerous to be vaccinated if you have already had the coronavirus?

A message received by the editorial staff of LCI.fr is concerned about the possible danger of a vaccine against Covid-19 for people already infected. We respond with Béhazine Combadière, director of research at Inserm.

Covid-19: a needle-free vaccination soon possible?

To meet the demand for vaccines, and to avoid a possible shortage of needles and syringes, start-ups, with the support of certain countries such as Canada, are working on injection methods that are not intramuscular, but through the skin.